|
Name |
(-)-beta-Sesquiphellandrene
|
| Molecular Formula | C15H24 | |
| IUPAC Name* |
(3R)-3-[(2S)-6-methylhept-5-en-2-yl]-6-methylidenecyclohexene
|
|
| SMILES |
C[C@@H](CCC=C(C)C)[C@H]1CCC(=C)C=C1
|
|
| InChI |
InChI=1S/C15H24/c1-12(2)6-5-7-14(4)15-10-8-13(3)9-11-15/h6,8,10,14-15H,3,5,7,9,11H2,1-2,4H3/t14-,15+/m0/s1
|
|
| InChIKey |
PHWISBHSBNDZDX-LSDHHAIUSA-N
|
|
| Synonyms |
beta-Sesquiphellandrene; (-)-beta-Sesquiphellandrene; 20307-83-9; (-)-(6R,7S)-sesquiphellandrene; (3R)-3-[(2S)-6-methylhept-5-en-2-yl]-6-methylidenecyclohexene; (-)-.beta.-Sesquiphellandrene; (R)-3-Methylene-6-((S)-6-methylhept-5-en-2-yl)cyclohex-1-ene; (R)-3-methylene-6-[(S)-6-methylhept-5-en-2-yl]-cyclohex-1-ene; .beta.-Sesquiphellandrene; T636HYS7CY; Cyclohexene, 3-[(1S)-1,5-dimethyl-4-hexen-1-yl]-6-methylene-, (3R)-; CYCLOHEXENE, 3-((1S)-1,5-DIMETHYL-4-HEXEN-1-YL)-6-METHYLENE-, (3R)-; CHEBI:64361; SESQUIPHELLANDRENE, (-)-.BETA.-; Q27133237; (6S)-2-Methyl-6-[(1R)-4-methylenecyclohex-2-enyl]hept-2-ene; (3R)-3-[(2S)-6-methylhept-5-en-2-yl]-6-methylidenecyclohex-1-ene; 2-HEPTENE, 2-METHYL-6-(4-METHYLENE-2-CYCLOHEXEN-1-YL)-, (1'R,6S)-(-)-; 1353-10-2
|
|
| CAS | 20307-83-9 | |
| PubChem CID | 12315492 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 204.35 | ALogp: | 5.4 |
| HBD: | 0 | HBA: | 0 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 0.0 | Aromatic Rings: | 1 |
| Heavy Atoms: | 15 | QED Weighted: | 0.547 |
| Caco-2 Permeability: | -4.535 | MDCK Permeability: | 0.00001690 |
| Pgp-inhibitor: | 0.588 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.012 |
| 30% Bioavailability (F30%): | 0.006 |
| Blood-Brain-Barrier Penetration (BBB): | 0.27 | Plasma Protein Binding (PPB): | 97.46% |
| Volume Distribution (VD): | 5.406 | Fu: | 2.80% |
| CYP1A2-inhibitor: | 0.879 | CYP1A2-substrate: | 0.355 |
| CYP2C19-inhibitor: | 0.377 | CYP2C19-substrate: | 0.859 |
| CYP2C9-inhibitor: | 0.354 | CYP2C9-substrate: | 0.382 |
| CYP2D6-inhibitor: | 0.031 | CYP2D6-substrate: | 0.308 |
| CYP3A4-inhibitor: | 0.534 | CYP3A4-substrate: | 0.454 |
| Clearance (CL): | 13.401 | Half-life (T1/2): | 0.219 |
| hERG Blockers: | 0.091 | Human Hepatotoxicity (H-HT): | 0.817 |
| Drug-inuced Liver Injury (DILI): | 0.388 | AMES Toxicity: | 0.022 |
| Rat Oral Acute Toxicity: | 0.027 | Maximum Recommended Daily Dose: | 0.457 |
| Skin Sensitization: | 0.967 | Carcinogencity: | 0.755 |
| Eye Corrosion: | 0.402 | Eye Irritation: | 0.959 |
| Respiratory Toxicity: | 0.9 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000383 | ![]() |
0.511 | D0M1PQ | ![]() |
0.367 | ||
| ENC002218 | ![]() |
0.414 | D0W6DG | ![]() |
0.207 | ||
| ENC002844 | ![]() |
0.390 | D03VFL | ![]() |
0.202 | ||
| ENC001981 | ![]() |
0.367 | D0O1UZ | ![]() |
0.182 | ||
| ENC000230 | ![]() |
0.346 | D0K5WS | ![]() |
0.178 | ||
| ENC000311 | ![]() |
0.346 | D02VPX | ![]() |
0.175 | ||
| ENC000796 | ![]() |
0.344 | D08SVH | ![]() |
0.171 | ||
| ENC001455 | ![]() |
0.333 | D0T2PL | ![]() |
0.171 | ||
| ENC000804 | ![]() |
0.333 | D02ZGI | ![]() |
0.171 | ||
| ENC003092 | ![]() |
0.328 | D0P4MT | ![]() |
0.171 | ||